| Completed | A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Inf NCT05082285 | GlaxoSmithKline | Phase 2 |
| Completed | A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Ad NCT04886154 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Completed | Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomita NCT04318548 | GlaxoSmithKline | Phase 3 |
| Completed | Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Health NCT04502693 | GlaxoSmithKline | Phase 3 |
| Completed | A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococc NCT03652610 | GlaxoSmithKline | Phase 2 |
| Completed | Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered NCT03621670 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACW NCT02986854 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK NCT02946385 | GlaxoSmithKline | Phase 2 |
| Completed | Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccin NCT02639351 | GlaxoSmithKline | Phase 1 |
| Completed | Safety of 4CMenB Exposure During Pregnancy NCT02640677 | GlaxoSmithKline | — |
| Completed | Combined Study - Phase 3b MenB Long Term Persistence in Adolescents NCT02446743 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations NCT02446691 | GlaxoSmithKline | Phase 4 |
| Completed | A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy NCT02451514 | GlaxoSmithKline | Phase 2 |
| Completed | Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study NCT02287688 | GlaxoSmithKline | — |
| Completed | Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry NCT02223637 | GlaxoSmithKline | — |
| Completed | Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Admin NCT02173704 | GlaxoSmithKline | Phase 3 |
| Completed | Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as NCT02212457 | GlaxoSmithKline | Phase 2 |
| Completed | Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Conco NCT02106390 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine NCT01934140 | Pfizer | Phase 3 |
| Completed | Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine M NCT01939158 | Pfizer | Phase 3 |
| Completed | The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencev NCT01962207 | Pfizer | Phase 3 |
| Completed | N. Meningitidis Carriage Study NCT01808365 | GlaxoSmithKline | — |
| Completed | Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children NCT01900899 | Pfizer | Phase 3 |
| Completed | Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administere NCT01777308 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co NCT01755689 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK1346 NCT01767376 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACW NCT01682876 | GlaxoSmithKline | Phase 3 |
| Completed | Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Hea NCT01641042 | GlaxoSmithKline | Phase 3 |
| Completed | Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children NCT01266993 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subject NCT01235975 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds NCT01154088 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healt NCT01165242 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-I NCT01144663 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612 NCT00974363 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612 NCT00955682 | GlaxoSmithKline | Phase 3 |
| Completed | Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Admini NCT00758264 | GlaxoSmithKline | Phase 3 |
| Completed | The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers NCT00718666 | GlaxoSmithKline | Phase 2 |
| Completed | The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/ NCT00715910 | GlaxoSmithKline | Phase 2 |
| Completed | Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated NCT00661557 | GlaxoSmithKline | Phase 2 |
| Completed | Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy C NCT00674583 | GlaxoSmithKline | Phase 3 |
| Completed | Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 79 NCT00614614 | GlaxoSmithKline | Phase 3 |
| Completed | Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects NCT00514904 | GlaxoSmithKline | Phase 3 |
| Completed | Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of E NCT00508261 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old NCT00471081 | GlaxoSmithKline | Phase 2 |
| Completed | Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old NCT00474266 | GlaxoSmithKline | Phase 3 |
| Completed | Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects NCT00464815 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 1 NCT00454909 | GlaxoSmithKline | Phase 2 |
| Completed | Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 1346 NCT00465816 | GlaxoSmithKline | Phase 3 |
| Completed | Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adult NCT00453986 | GlaxoSmithKline | Phase 3 |
| Completed | Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 1 NCT00427908 | GlaxoSmithKline | Phase 2 |
| Completed | Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine NCT00390143 | GlaxoSmithKline | Phase 2 |
| Completed | Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate NCT00356369 | GlaxoSmithKline | Phase 2 |
| Completed | Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects NCT00317109 | GlaxoSmithKline | Phase 3 |
| Completed | Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-01 NCT00291343 | GlaxoSmithKline | Phase 3 |
| Completed | Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years NCT00290329 | GlaxoSmithKline | Phase 4 |
| Completed | Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Do NCT00126945 | GlaxoSmithKline | Phase 2 |
| Completed | Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate NCT00126984 | GlaxoSmithKline | Phase 2 |
| Completed | Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACW NCT00227422 | GlaxoSmithKline | Phase 4 |
| Completed | Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old NCT00196976 | GlaxoSmithKline | Phase 2 |
| Completed | Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 NCT00196963 | GlaxoSmithKline | Phase 2 |
| Completed | Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine NCT00271479 | Epicentre | Phase 4 |
| Completed | Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subje NCT00196950 | GlaxoSmithKline | Phase 2 |
| Completed | Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddler NCT00135564 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Ado NCT00137917 | GlaxoSmithKline | Phase 2 |
| Completed | Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants NCT00135486 | GlaxoSmithKline | Phase 2 |